Subconjunctival Mitomycin C Injection into Pterygium Decreases Its Size and Reduces Associated Complications
Year: 2016
Type: book-chapter
Study design: Clinical Trial
Abstract: Purpose: To evaluate the safety and efficacy of subconjunctival injection of low dose mitomycin C (MMC) in the management of pterygium.Patients and Methods: This study was carried out from February 2006 to April 2007 in the eye clinic of Vali-e-Asr Hospital of Birjand University of Medical Sciences.Forty eyes with primary pterygia received 0.02 mg MMC (0.1 ml of 0.2 mg/ml solution, Kyowa Hakko Kogyo Co. Ltd., Tokyo, Japan) subconjunctivally injected into the body of the pterygium.Patients were followed at one day, one week, one month, six months and one year after injection.Patients were examined at all visits for conjunctivally erythematic, epithelial defects; intraocular pressure; topography; keratometry; and other complications (complete slit-lamp examinations).Results: The only complications after subconjunctival MMC injection were mild chemosis, long discomfort, and redness in the site of injection for four days, which were seen in six patients (15%).Toxicity of MMC was not observed in any case.The size of pterygia reduced in 83% of cases and progression were not seen in any case.The amount of astigmatism reduced in 70% cases (mean 0.27 diopter).Conclusion: Subconjunctival injection of MMC is an effective treatment and allows exact titration of MMC delivery to the activated fibroblasts and minimizes epithelial toxicity but long term follow up is required.
Source: InTech eBooks
DOI: 10.5772/60090
Institution: Birjand University of Medical Sciences
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W2276188174